HDAC inhibitors show 0.65 pooled favorable response rate in advanced head and neck cancer
HDAC Inhibitors Show Promise for Advanced Head and Neck Cancer
This meta-analysis of single-arm trials evaluated HDAC inhibitor therapy for advanced head and neck cancer. The analysis found a pooled cumu…
A review of clinical trials shows that HDAC inhibitors may help patients with advanced head and neck cancer when used in combination with ot…
Systematic review and meta-analysis on NY-ESO-1 expression in triple-negative breast cancer
A Hidden Protein in Aggressive Breast Cancer May Unlock New Treatments
This meta-analysis of 12 studies in 1,545 TNBC patients found a pooled NY-ESO-1 expression prevalence of 16.1%. The authors note substantial…
A protein found in about one in six triple-negative breast cancers could open the door to immune-based treatments that target cancer cells w…